Patients With Cirrhosis Require More Fecal Microbiota Capsules to Cure Refractory and Recurrent Clostridium difficile Infections.

Affiliation

Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: [Email]

Abstract

The incidence of recurrent and refractory Clostridium difficile (rCDI) is increasing.1 Cirrhotic patients are at increased risk of CDI as a result of frequent hospitalizations, prophylactic antibiotics, proton pump inhibitor use, and comorbidities.2 In addition, cirrhotic patients with CDI have a higher mortality rate, longer length of stay, and a higher cost compared with noncirrhotic patients.3.